Two years ago I posted a video about Medicare overpaying for a cancer drug. It did 3 million views. New CMS data just came out. It got worse in a way I did not expect. Imatinib treats leukemia. It went generic in 2016. Here is what Medicare Part D spent on it in 2025: $196.7 million. One molecule. One year. Generic imatinib: 17,047 patients at $967 per prescription. Brand Gleevec: 881 patients at $10,112 per prescription. 881 people ran up $66.9 million. That is 4.9% of imatinib patients consumi

Direct questions from App T&D in UPSC cms 2026. #neetpg #upsccms #inicet